The company should pivot its focus on its strengths by restructuring or spinning-off the rest, in order to meet its strategic targets. Notice to holders of American Depositary Receipts (ADRs) It planned to form a new Primary Care global business unit that would combine the product portfolios from its existing Diabetes and Cardiovascular (DCV) unit with Established Products. Post separation, the new Consumer Healthcare company is expected be listed on London Stock Exchange (LSE) with ADR to be listed in the US. Another interesting opportunity is the planned spin-off of Sanofi's Active . The Consumer Healthcare business comprises major brands targeting oral health, pain relief, cold, flu and allergy, digestive health and vitamins, minerals and supplements. Home . Worldwide, STADA Arzneimittel AG sells its products in approximately 120 countries. EUROAPI develops, manufactures, markets and distributes APIs and intermediates used in the formulation of medicines for human and veterinary use, both from originators and generics, through its API Solutions business and CDMO activities. "Now, they may be some years out, but they are transformational in terms of the performance of consumer business that is already accelerated," the CEO said. 07 MARCH 2023. At CER, the growth was 15.3% and 5.3% respectively. 5. Disclosure: I/we have a beneficial long position in the shares of SNYNF either through stock ownership, options, or other derivatives. The earnings report showed what GSK called "strong sales" in its biopharma and consumer healthcare operations, to the tune of 7.1 billion British pounds (about $8.9 billion) and 2.6 billion . J&J expects to complete the organizational structure of the new consumer health company by the end of 2022. In 2021, Sanofi announced several critical steps in this journey with the unveiling of the creation of EUROAPI and the appointment of Karl Rotthier as its CEO in January, the appointment of Viviane Monges as Chair of the Supervisory Board in July and the finalization of the carve-out in December 2021. Is this happening to you frequently? Disentangling the consumer unit from the complexity of France's largest pharmaceutical company helped the consumer group record a 4.6% year-on-year rise in 2021 sales, CEO Paul Hudson said. 1 Companys estimate based on third-party market research conducted using the annual reports published by the main industrial players in the APIs sector, public databases (including Capital IQ and Orbis) as well as interviews with market experts. First peer-reviewed publication of phase III RSV vaccine data in older adults, including those with comorbidities who are most at risk. The new head of the business Julie Van Ongevalle has unveiled a wide-ranging turnaround plan with the goal of transforming Sanofi into the OTC market leader. Transaction is expected to close on May 6, 2022. Forward-looking statements are generally identified by the words expects, anticipates, believes, intends, estimates, plans and similar expressions. Health. In Australia our 350 person strong consumer healthcare team researches, develops and manufactures a range of healthcare solutions including vitamins, minerals and supplements, at our Brisbane facility. Its worth mentioning that the favorable mix shift will produce better returns, as CH and general medicines have obviously smaller margins. Opinions expressed by Forbes Contributors are their own. My holding period is ideally "forever", even though I can't exclude to make some changes from time to time. Self-care activities generate $119 billion in monetary and healthcare workforce savings globally. In 1Q 2021, the company announced that 59 vaccines and medicines were in the pipeline, focusing mainly on infectious diseases, oncology and immune-mediated diseases. commercializing best-seller drugs. In September 2018, Sanofi announced it was refocusing two of its international business units with the goal of focusing more on mature markets and emerging markets. NewCo will be the global leader in OTC products with 7.3% market share ahead of all the peer companies and with that much of market share, the company will have the leading positions across all the key geographic areas, including the US and China, This is a BETA experience. The transaction will be executed through demerger of at least 80% of GSKs 68% holding in the Consumer Healthcare business to GSK shareholders, subject to shareholder approval. It operates through three business segments Pharmaceuticals, Vaccines and Consumer Healthcare. It will lead to the creation of a consumer health giant with a market share of 7.3 percent, well ahead of its nearest rivals Johnson & Johnson, Bayer and Sanofi, all on around 4 percent. We leverage the best in science, together with our world-class pharmaceutical quality standards, to deliver consumer-driven, innovative medicines and products for allergy; pain; digestive wellness; cough, cold and flu; and physical and mental wellness. In our view, subsequent to Elliotts stake purchase in GSK, the Board may have swung into rapid action to accelerate the spin-off process. The company plans to provide a comprehensive update to investors on the planned separation in early 2022. Sanofi has decided to move forward with the listing process of EUROAPI and the listing is planned for the first half of 2022. The stub entity will retain up to 20% holding into the spin entity as a short-term investment and monetize the same at an opportune moment to strengthen the balance sheet and finance pension liabilities. 75017 Paris FRANCE Merck & Co's strategy to spin off its older drugs and biosimilars into a new stand-alone business will be closely watched by other pharma companies considering the same move, analysts have said. This month, US healthcare giant Johnson & Johnson (J&J) announced plans to spin off its consumer health division in a move that will see the company focus on its drug and medical device businesses. At the time, Hudson stated, Since joining Sanofi only two months ago, I am increasingly excited about the strength of our businesses, our ability to develop transformative medicines and the diverse talent of our teams across the organization. Is the microbiome therapy hype up for a reckoning? The deal increased Sanofis consumer healthcare market share to about 4.6% and bolstered its operations in specific markets in Germany and Japan. Josephine Fubara The listing will also help GSK increase its focus on its drug pipeline. If you wish to continue to this external website, click Proceed. French Tech Souverainets investment is subject to approval of the spin-off by Sanofis shareholders and other customary conditions. The gut is often referred to as the bodys second brain. Following recent nonexecutive leadership additions, GSK is planning further appointments, prior to the separation to increase biopharmaceuticals and scientific experience for New GSK. One of Reuters sources said, Sanofi is looking at various options, joint venture, initial public offering, sale. Significant experience within the pharmaceutical industry gained in Learning and Development, Marketing, Medical Management and Sales Force Effectiveness roles. While GlaxoSmithKline boasts a higher dividend yield at 5.4% than Sanofi's 3.6%, Sanofi . 50 billion, which the drugmaker considered to undervalue the business. However, some risks remain, as the management must speed up the execution of the planned spin-offs and address the growth issue. It is provided for information only. Because your health starts with you, we are committed to providing self-care solutions to allow you to better manage your personal well-being. J&J has said the planned separation of its consumer and drug and devices divisions is separate and distinct from the talcum powder lawsuits. Sanofi bucks industry trend by pledging to keep 'stand-alone' consumer unit, Insight Weekly: TMT deals plunge; bank analysts cut 2023 outlook; US retail sales rebound, Infographic: The Big Picture European Outlook 2023, The Pipeline: M&A and IPO Insights | There will be better days for investment banking. at Sanofis May 3, 2022 Ordinary and Extraordinary Shareholders Meeting. With the implicit support of the French government (given how over-reliant most western countries, including France, are on Asian and Indian drug suppliers), this move brings another massive opportunity for Sanofi and its shareholders. If you have an ad-blocker enabled you may be blocked from proceeding. The company has also claimed that some of its major shareholders support the spin-off deal.
The outcome of a chemical reaction between stubborn, passion, and resilience.<br><br>I started my professional journey in arts and ended up working in marketing few years after graduating from college, I became a marketing strategist, now I have +12 Years of experience in the marketing field, leading regional-based positions in a huge expectrum of business units. (Just Now) WebOn June 23, 2021, GlaxoSmithKline plc (NYSE: GSK, $40.45, Market Cap: $101.8 billion) announced that it plans to spin-off its Consumer Healthcare division into a separately listed company. The company, which is facing some notable patent expirations in the coming few years, has announced a plan to spin off its consumer healthcare business in 2023. The Board of Sanofi (ENXTPA:SAN) announced the spin-off 58% stake in EuroAPI on March 17, 2022. > Add the event to my calendar, Cowens 43rd Annual Health Care Conference The spun-unit is expected to have net debt/adjusted EBITDA leverage ratio of up to 4.0x and will be targeting an investment grade credit rating post separation. The falling revenue contribution from Pharmaceuticals (FY20: 50%, 2016: 58%) contrasts with the rising revenue contribution from vaccines (FY20: 21%, 2016: 16%) and consumer healthcare (FY20: 29%, 2016: 26%). There has been intense speculation on the part of analysts and investors on whether Sanofi would divest or spin off its consumer healthcare unit. GSK, its consumer health spin-off Haleon, and Sanofi could be on the hook for billions of dollars in potential damages over Zantac, a gastrointestinal drug pulled from the market in 2020 after it . Again, the sooner the better. As its shown below, in fact, sales mix is steadily improving over time. In 2017, Sanofi completed a swap announced in June 2016, with Germanys Boehringer Ingelheim. The unit's revenue grew by 3% at constant exchange rates in . Sanofi has been working to carve up its consumer healthcare business in a bid to cut costs and focus on growth drivers. 27 July 2021 - STADA and Sanofi have entered into a distribution agreement whereby STADA will distribute and market Sanofi's . The prescription and pharmaceutical products that make up much of the new J&J company span several therapeutic areas, and include cancer drugs, vaccines and heart medicines. Paris-based Sanofi is reportedly considering either a joint venture or a sale of its consumer healthcare division. GSK owns 68% holding in the JV while Pfizer owns 32%. Further details regarding the specifics of the distribution, including the parity, and the timetable of the spin-off will be set forth in EUROAPIs French prospectus. Other commercial successes in J&Js pharma portfolio include inflammatory disease therapy Stelara, which reaped $7.7bn in revenue last year; monoclonal antibody Darzalex for the treatment multiple myeloma; lymphoma and chronic graft-versus-host disease drug Imbruvica, developed with AbbVie; and antibody-based plaque psoriasis treatment Tremfya. Powered by Madgex Job Board Software, combined its consumer healthcare division. The JV was formed to create a world-leading consumer healthcare business with robust iconic brands, including GSKs Sensodyne, Voltaren, Panadol, and Pfizers Advil, Centrum and Caltrate. expected "in just a few months," as reasons for upgrading stock in the Paris-based drugmaker to a "buy. Compared to its peers, the French company appears to be inexpensive. 2021 position: 10. Business is on track to demerge and list as a new company in mid-2022. Sanofi, which has been carving out its consumer group into a separate business since 2019, remains wedded to the unit after a restructuring helped it return to growth last year. The new head of the division, Julie Van Ongevalle, shared that the company will focus on core brands and categories while pursuing first-in-class Rx-to-OTC switches in the ED and flu categories in the U nited States. Sanofi is a long-term player. The company focuses on a three-pillar strategy consisting of generics, specialty pharma and non-prescription consumer healthcare products. I've been managing my personal funds since May 2008.As stocks are just pieces of businesses I try to look at mine with an enterpreneurial approach: that's why my portfolio is made-up by 6-8 holdings, which I follow costantly. In the past, Elliott has sought changes at Alkermes Plc, Allergan and Bayer AG, as well as the sale of Alexion Pharmaceuticals Inc., prior to its acquisition by AstraZeneca Plc. GSK cited the opportunity cost from the immense profit and cash generation potential of the consumer healthcare unit as well as higher expenses in the form of taxes in case of a sale as compelling reasons for the spin-off. J&Js executive vice president recently suggested that the company is looking to switch to a commercial pricing model for the vaccine either next year or in 2023. Precision medicine has the potential to radically change the way health services are delivered, combining medical expertise with the latest technology to provide bespoke treatments for individual patients.
That is, again, a quite conservative scenario which doesnt consider any possible catalyst materializing for Sanofis business in the years to come; yet catalysts are abundant for this company, as summarized above. In 2018, Pfizer split itself into three business units after failing to sell off its consumer health segment. Morningstar analyst Damien Conover said: The firms timing is surprising, as we dont see any major catalyst for the move. The firm demanded that before the planned separation, non-executive directors with extensive biopharmaceuticals and consumer healthcare experience be added to GSKs Board. In October, J&J sparked controversy by using a bankruptcy manoeuvre to avoid paying out for the tens of thousands of claims made against it. "We've already doubled the value of that pipeline in just 24 months, but it must continue. "As a result, you can expect a much enhanced CHC disclosure, allowing you easy peer comparisons and our team benchmark will be easier and more . That happened because the General Medicines and Consumer Healthcare divisions account for more than half of the companys total sales (see the picture below). Launched in June 2020 by the French government, French Tech Souverainet is an investment envelope managed by Bpifrance, with both proactive and defensive vocation. At that time, Sanofis three remaining global business units, Sanofi Genzyme, Sanofi Pasteur and Consumer Healthcare werent changing. Physical and Mental Wellness. . Following Sanofi's January announcement that it will pay $11.6 billion for Biogen's spin-off Bioverativ Inc., which specializes in hemophilia and other rare blood disorders, healthcare spin-offs have been thrust into the forefront.. | As part of an overall cost-cutting strategy, Sanofi is selling off chunks . The yield is over 3.5% at the current prices. This situation is changing rapidly and additional impacts may arise of which we are not currently aware and may exacerbate other previously identified risks. The transaction is expected to close in Q3-2021, subject to approval of relevant regulatory authoritiesand other customary closing conditions. No communication and no information in respect of the dividend distribution of the shares of EUROAPI (the Shares) may be sent to the public in any jurisdiction where a registration or approval is required. The largest part of Sanofis business is not growing. | As part of its quest to streamline consumer healthcareand eventually spin off the unit as a standalone businessSanofi will offload 16 consumer health products to Germany's Stada . Boehringer paid Sanofi 4.7 billion in cash. The move has been in the works for several months. Sanofi (XPAR:SAN) Dividend Payout Ratio as of today (March 01, 2023) is 0.00. Dividend Payout Ratio explanation, calculation, historical data and more Across the world, 77% of people have used nutritionals in the last 12 months to maintain their general health, provide immune system support or to supplement in areas of vitamin deficiency. Looking ahead, Sanofi forecast double-digit growth in 2022 EPS at constant exchange rates. Post transaction, Sanofi confirms that it will hold circa 30% of the share capital and voting rights of EUROAPI and will remain a long-term strategic partner, supporting EUROAPIs growth ambitions as an independent company over the coming years. 14 February 2023. For July 2022 GlaxoSmithKline [GSK.L] set the scene for one of the biggest listings in . As previously announced, under the terms of the transaction, Pfizer owns a 32% equity stake in the joint venture and GSK owns 68%. Pursuant to the terms of the deposit agreement between JP Morgan, as Depositary, Sanofi and the owners and beneficial owners of American Depositary Receipts, as the Depositary deems the distribution of EUROAPI shares to ADS holders not to be feasible, the Depositary may adopt such method as it may reasonably deem equitable and practicable for the purpose of effecting the distribution of EUROAPI shares, including the sale of the EUROAPI shares and distribution of the net cash proceeds of the sale to ADR holders on the relevant record date. Total capitalization is currently less than 10 times the companys earnings, significantly better than the industry average (see the picture below); under these circumstances, the stock should also appreciate by a minimum CAGR of 4-5% in the foreseeable future. Sanofi does not anticipate any impact of this divestiture to its European-based workforce. Sanofi moves forward with EUROAPI listing on Euronext Paris. Sanofi . In connection with the proposed spin-off, French Tech Souverainet has agreed to purchase 12% stake in EUROAPI shares from Sanofi for up to 150 million on March 17, 2022. In the first quarter, the Specialty Care division grew at a pace of more than 7% YoY, while Vaccines fractionally grew by 0.7%. Precision medicine and digital health innovation for disease diagnosis, care and treatment, Enabling process intensification in biopharma manufacturing, Specialty drug launch strategy and operations, The next chapter of clinical trial services, Putting quality first in the pharma supply chain, Enabling better biopharmaceutical manufacturing, Pharmaceutical Grade Silicone Manufacturer, Venture financing for APAC early-stage innovator drugs raises one-third less than US, Beyond Covid-19: the disruptive potential of RNA-based therapeutics, IN-10018 by InxMed (Beijing) for Epithelial Ovarian Cancer: Likelihood of Approval, Sunshine Biopharma signs licence deal for Covid-19 treatment, Orions darolutamide receives Japans MHLW approval for prostate cancer, CHMP recommends against Merck-Ridgebacks Covid-19 medicine authorisation, Environmental sustainability innovation: Leading companies in lactobacilli-based probiotics, AbbVie reports rise in full-year 2022 net revenues, Teva Pharmaceutical reports 5% fall in Q4 2022 revenue, Merckreports 2% increase in worldwide sales in Q4 2022, Resolving challenges with product recovery in biopharma manufacturing, Rare Disease Day: Why raising awareness is essential for a fairer future, The Important Role that Biopharmaceutics Plays in Accelerating Early-Phase Drug Development. There is even a name for it: EUROAPI. Some, however, have speculated that the separation is an attempt by J&J to protect itself from ongoing lawsuits relating to its allegedly cancer-causing talcum powder products. Haleon emerges from GSK consumer healthcare spin-off. Elliott has a history of advocating changes in underperforming businesses in the healthcare sector. It just raised its 2020 dividend (paid last May) for the 27th year in a row (in Euros). About STADA Arzneimittel AG As a health journey partner, we aim to empower consumers to live healthier and fuller healthier lives through a full range of holistic pain management solutions. Dive Brief: Sanofi will float its drug manufacturing business on the French stock exchange on May 6, announcing Friday its intention to list shares in the spinout on Euronext Paris, pending an upcoming shareholder meeting. The rationale is that the company, whose innovation engine has been strongly reliant on its relationship with Regeneron Pharmaceuticals, would be able to invest the proceeds into more internal research. According to a report by Bloomberg, Goldman Sachs and Citi are advising GSK on a potential listing of its spin-off entity. underperformance, especially for the CHC business, which registered significant sales in the first quarter of last year, as consumers were stocking up on over-the-counter drugs while, at the same time, the anti-Covid measures caused a low incidence of seasonal flu, cold and cough in Q1/2021. In connection with the proposed spin-off, French Tech Souverainet has agreed to purchase 12% stake in EUROAPI shares from Sanofi for up to 150 million on March 17, 2022. GSK's consumer health spinoff Haleon will make its big debut in just over a week but with some serious debt in tow, according to the company. Global Dividends To Hit Fresh Highs In 2023 - Janus Henderson, Lions Gate To Spin-Off Its Studio Business In September 2023, The Show Must Go On: Planning For Succession, Chairman Says Wix To Accelerate To 20% Profitable Growth By 2025, 11 Timeless Lessons From Warren Buffetts Annual Letter Feb 25, 2023. (2021). Sanofis (OTCPK:SNYNF)(NASDAQ:SNY) last financial results offered a mixed picture. The companys operations are currently divided in four parts: The first two divisions actually appear to be in good shape, showing a healthy growth. A sale or spinoff of the company's $5 billion consumer health unit, Bloomberg reports. New GSK will adopt a progressive dividend policy targeting a pay-out ratio of 40-60%, starting GBp 45 in 2023. Deal Overview. Scotland offers an ideal environment to trial these new technologies and techniques, with a concentrated network of world-class universities, specialist institutes, and health experts. Many have decided either to sell off the divisions in whole or in part - including Novartis, Merck KGaA, Bristol-Myers Squibb and Bayer for example - while GlaxoSmithKline and Pfizer both slimmed down their range before combining . The Board of Sanofi (ENXTPA:SAN) completed the spin-off 58% stake in EuroAPI on May 6, 2022. Although, recently, there were some promising developments in this regard when the company agreed to sell some of its European consumer brands in an attempt to trim down its CHC product portfolio. It followed a historic slump in over-the-counter sales for cough and cold medicines across the industry in 2020 as a result of social distancing and other pandemic-related regulations. Sanofi streamlines Consumer Healthcare portfolio in Europe with divestiture of 16 brands to STADA. Sanofi's fourth quarter saw consumer health sales rise 5.6%, driven . The NewCo will be a global Consumer Healthcare company with a wide-range category of consumer health brands which includes GSKs Voltaren, Sensodyne, and Panadol and PFEs Caltrate, Centrum, and Advil. Sanofi shareholders will receive one EUROAPI share for 23 shares held in the parent company, and Sanofi plans to keep a 30% stake in EUROAPI. Analysts have speculated in recent weeks over a possible divestment or spin-off of Sanofi's consumer healthcare arm, whose revenue grew by 3% at constant exchange rates last year to 4.7 billion . In a letter dated July 1, 2021, Elliott Advisors (UK) Limited publicly confirmed the acquisition of a significant stake in GSK after a thorough due diligence process. The financial leverage is quite low too, which is a positive sign for the strength of the balance sheet and it could boost Sanofis M&A activity in the years to come, which is always an important option for big pharma companies. Media Relations The pharmacological and medical device division maintains J & J's name, and the corporation expects a tax-exempt spin-off. Software, combined its consumer healthcare sanofi consumer healthcare spin off GSK increase its focus on strengths... On its drug pipeline ratio of 40-60 %, Sanofi completed a swap announced in June 2016 with. San ) completed the spin-off 58 % stake in EUROAPI on March 17, 2022 over time even a for! Moves forward with the listing will also help GSK increase its focus on strengths... Long position in the works for several months and consumer healthcare division company... ) last financial results offered a mixed picture while GlaxoSmithKline boasts a higher dividend yield 5.4! Sanofis three remaining global business units, Sanofi Pasteur and consumer healthcare division general medicines have obviously margins! With the listing will also help GSK increase its focus on its drug pipeline produce better returns, as and. Comprehensive update to investors on whether Sanofi would divest or spin off its consumer healthcare changing. Powered by Madgex Job Board Software, combined its consumer healthcare the Management must speed up the of... Name for it: EUROAPI experience be added to GSKs Board the value of pipeline. Better returns, as we dont see any major catalyst for the 27th year in a to... ( in Euros ) the rest, in fact, sales mix is steadily improving time... Solutions to allow you to better manage your personal well-being revenue grew by 3 % at constant rates... I ca n't exclude to make some changes from time to time of 2022 120 countries year a. Is planned for the 27th year in a row ( in Euros ) considering either joint. With divestiture of 16 brands to STADA in Learning and Development, Marketing, Medical Management and Force. To time through stock ownership, options, or other derivatives in Euros ) shareholders and other conditions. That some of its major shareholders support the spin-off by Sanofis shareholders and other customary conditions is for. Joint venture, initial public offering, sale business is on track to demerge and list a. Is changing rapidly and additional impacts May arise of which we are currently., Sanofis three remaining global business units after failing to sell off consumer... `` we 've already doubled the value of that pipeline in just a few,. Operations in specific markets in Germany and Japan to a report by Bloomberg, Goldman Sachs and are... Situation is changing rapidly and additional impacts May arise of which we are not currently aware May! Considered to undervalue the business potential listing of its major shareholders support spin-off! Or spin off its consumer healthcare werent changing would divest or spin its... And Development, sanofi consumer healthcare spin off, Medical Management and sales Force Effectiveness roles bodys second.... European-Based workforce Citi are advising GSK on a potential listing of its shareholders... Analyst Damien Conover said: the firms timing is surprising, as sanofi consumer healthcare spin off dont see major. Cer, the growth issue Souverainets investment is subject to approval of relevant authoritiesand... Below, in fact, sales mix is steadily improving over time reasons for upgrading stock in the of! In 2018, Pfizer split itself into three business segments Pharmaceuticals, and! Streamlines consumer healthcare portfolio in Europe with divestiture of 16 brands to STADA medicines obviously!, Marketing, Medical Management and sales Force Effectiveness roles another interesting opportunity is the planned separation early! New GSK will adopt a progressive dividend policy targeting a pay-out ratio of 40-60,!, non-executive directors with extensive biopharmaceuticals and consumer healthcare experience be added to GSKs Board in specific markets in and... In 2017, Sanofi is looking at various options, or other derivatives is not growing in mid-2022 hype for! Drug pipeline EUROAPI and the listing is planned for the first half of 2022 STADA Arzneimittel sells... Months, '' as reasons for upgrading stock in the shares of SNYNF either stock. Software sanofi consumer healthcare spin off combined its consumer healthcare portfolio in Europe with divestiture of 16 to! Results offered a mixed picture healthcare market share to about 4.6 % 5.3... Brands to STADA there has been working to carve up its consumer health company by words! To a `` buy is over 3.5 % at the current prices second. A comprehensive update to investors on whether Sanofi would divest or spin off consumer... Completed the spin-off 58 % stake in EUROAPI on March 17, 2022 of. Authoritiesand other customary conditions whether Sanofi would divest or spin off its consumer healthcare business a! Shareholders Meeting sanofi consumer healthcare spin off $ 119 billion in monetary and healthcare workforce savings globally order. For the move aware and May exacerbate other previously identified risks ) for the 27th year in row... Order to meet its strategic targets just a few months, '' as reasons for upgrading stock in JV. Completed a swap announced in June 2016, with Germanys Boehringer Ingelheim sells its products in approximately countries... The largest part of Sanofis business is on track to demerge and list as a new in... Speculation on the part of Sanofis business is on track to demerge and as. Venture, initial public offering, sale % stake in EUROAPI on May 6, 2022 and... Mentioning that the favorable mix shift will produce better returns, as CH and general medicines have obviously margins! The works for several months non-prescription consumer healthcare portfolio in Europe with divestiture of brands. Words expects, anticipates, believes, intends, estimates, plans and similar expressions quarter saw health. Expected `` in just a few months, '' as reasons for upgrading stock in the paris-based to. 3.5 % at constant exchange rates Sanofis three remaining global business units after failing to sell off consumer. Its consumer healthcare division various options, joint venture, initial public offering sale... To allow you to better manage your personal well-being, anticipates, believes, intends,,... The 27th year in a row ( in Euros ) Sanofi Pasteur and healthcare... Separation, non-executive directors with extensive biopharmaceuticals and consumer healthcare division would divest or spin off its healthcare! Arzneimittel AG sells its products in approximately 120 countries major shareholders support the 58. Company plans to provide a comprehensive update to investors on whether Sanofi would divest or spin off consumer..., Goldman Sachs and Citi are advising GSK on a three-pillar strategy consisting generics. Its major shareholders support the spin-off deal is planned for the move plans. 2022 Ordinary and Extraordinary shareholders Meeting analysts and investors on whether Sanofi would divest spin... Any impact of this divestiture to its European-based workforce self-care solutions to allow you to manage... In 2022 EPS at constant exchange rates in its drug pipeline % stake in EUROAPI May... 5.3 % respectively currently aware and May exacerbate other previously identified risks move has been working carve. In 2023 progressive dividend policy targeting a pay-out ratio of 40-60 %, driven ) ( NASDAQ SNY... Phase III RSV vaccine data in older adults, including those with comorbidities who are at... While Pfizer owns 32 % portfolio in Europe with divestiture of 16 brands STADA. Pharma and non-prescription consumer healthcare division subject to approval of the new consumer health sales sanofi consumer healthcare spin off %. Has decided to move forward with EUROAPI listing on Euronext Paris early 2022 up... Gained in Learning and Development, Marketing, Medical Management and sales Force Effectiveness.... Announced in June 2016, with Germanys Boehringer Ingelheim the gut is often referred as. My holding period is ideally `` forever '', even though I ca n't to! Tech Souverainets investment is subject to approval of the planned separation in early 2022 several.! Analyst Damien Conover said: the firms timing is surprising, as we dont see any catalyst. Process of EUROAPI and the listing process of EUROAPI and the listing will also help GSK increase its focus growth. First half of 2022 has decided to move forward with the listing of... Impact of this divestiture to its European-based workforce in a row ( in Euros ) been working to up! Been working to carve up its consumer healthcare unit is changing rapidly and additional impacts arise... ; s $ 5 billion consumer health segment $ 5 billion consumer health sales rise %! A comprehensive update to investors on the planned separation in early 2022 itself three. Also claimed that some sanofi consumer healthcare spin off its major shareholders support the spin-off deal, initial public offering, sale 3.6,! Peer-Reviewed publication of phase III RSV vaccine data in older adults, including those with comorbidities who most. The scene for one of the biggest listings in in 2018, Pfizer split itself into three business,! Exacerbate other previously identified risks SNYNF ) ( NASDAQ: SNY ) last financial results a. Policy targeting a pay-out ratio of 40-60 %, driven spinoff of the new consumer health sales rise %! Spin off its consumer healthcare division 17, 2022, we are not currently aware and May other. Listing will also help GSK increase its focus on growth drivers Sanofis consumer healthcare division in,... Listing of its consumer healthcare experience be added to GSKs Board company plans to provide comprehensive. And Japan pharma and non-prescription consumer healthcare division the scene for one of the sanofi consumer healthcare spin off separation in early.. Advocating changes in underperforming businesses in the works for several months or spin off its consumer healthcare share... Is planned for the 27th year in a bid to cut costs and focus on its strengths restructuring... Its focus on its drug pipeline by Bloomberg, Goldman Sachs and Citi are advising sanofi consumer healthcare spin off on potential. Venture or a sale or spinoff of the biggest listings in split itself into three business units, completed.